Cramer: Celgene has phenomenal pipeline
Mad Money’s Jim Cramer highlights winning biotech names out of the American Society of Hematology Annual Meeting.
As the market licks its wounds from the hideous decline in oil prices, Jim Cramer would like to remind investors that there is one leg of the industry that has no economic sensitivity whatsoever to the price of oil: biotechs. […]
Source: Biogen IdecAs the year begins to come to a close, biotechnology investors are right to wonder what stocks may be worth owning as we head into 2015. We asked three of our Motley Fool analysts to tell us which three biotechnology stocks will be in their stockings this holiday season. Read on to see which three companies they chose.Cheryl […]
Source: Celgene CorporationThe biotechnology industry has been one of the best performing baskets in the stock market this year, but just because biotech stocks were kind to investors this year doesn’t necessarily mean that they’ll rally next year, too.Biotech stocks can move significantly higher or lower in any given year due to investor’s reaction to data from ongoing drug trials, […]
More:
Biotech ETFs in Focus on Cubist Takeover Deal
[…]
View photo.The biotech stocks are hitting fresh new highs to start the week after the announcement of yet another multi-billion dollar deal. Pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has agreed to purchase advanced antibiotic pharmaceutical company Cubist Pharmaceuticals Inc (NASDAQ: CBST) for $9.5 billion.The deal breaks down to Merck paying about $102 a share, a 37-percent premium from […]
View gallery.The S&P 500 and Dow Jones Industrials continue to march higher. At some point the party will end, but for now, new highs are a daily occurrence.Some of the best performing industries over this latest market tear have been airlines, metals and semiconductors.However, as has been the case for most of the year, biotechnology has also been one of […]
The stock market has been racing higher at nearly unprecedented levels in recent years. Even so, the healthcare sector in general, and biopharma stocks in particular, have still managed to crush the broader markets over the last few years. Since 2012, for instance, the iShares Nasdaq Biotech Index has more than tripled the returns of the closely watched S&P 500:Perhaps […]
Biotechnology stocks have been among the market’s top performers this year, with the iShares Nasdaq Biotechnology ETF’s 36% gain handily outpacing the S&P 500 ‘s 14% return. That heady return, however, comes with one potential drawback: It might be tough to figure out which biotech stocks will continue climbing next year. With that in mind, here are three large-cap biotech […]
See original article:
Rare disease could be the gateway to billions …
See which stocks are being affected by Social Media
[…]
ORLANDO, Fla., Dec. 5, 2014 (GLOBE NEWSWIRE) — A shelf registration (commonly known as an S-3 filing) is a public offering which allows companies to offer and sell securities without having to file separate prospectuses for each raise. Typically, the maximum amount that can raised through one of these documents is $100 million. Looking at biotech and medtech stocks that […]
